1000577-76-3

Upstream product

• 60811-21-4 1-bromo-3-chloro-4-fluorobenzene 
• 1280786-80-2 5-bromo-3-chloro-2-fluorobenzaldehyde 
• 161957-55-7 3‐chloro‐2‐fluorobenzoic acid 

Downstream Products

• 1386460-01-0 3-chloro-2-fluoro-5-morpholin-4-yl-benzonitrile 
• 1386460-20-3 3-aminomethyl-5-chloro-4-fluoro-N,N-dimethyl-benzamide 
• 1386460-19-0 (3-chloro-5-dimethylcarbamoyl-2-fluoro-benzyl)-carbamic acid tert-butyl ester 
• 1386460-06-5 (3-aminomethyl-5-chloro-4-fluoro-benzyl)-diethyl-amine 
• 1386460-05-4 (3-chloro-5-diethylaminomethyl-2-fluoro-benzyl)-carbamic acid tert-butyl ester 
• 1386460-04-3 (3-chloro-2-fluoro-5-formyl-benzyl)-carbamic acid tert-butyl ester 
• 1386460-03-2 (3-chloro-2-fluoro-5-vinyl-benzyl)-carbamic acid tert-butyl ester 
• 1386460-02-1 3-chloro-2-fluoro-5-morpholin-4-yl-benzylamine 
• 1386459-93-3 (3-aminomethyl-5-chloro-4-fluoro-phenyl)-(2-methoxy-ethyl)-methyl-amine 
• 1386459-92-2 {3-chloro-2-fluoro-5-[(2-methoxy-ethyl)-methyl-amino]-benzyl}-carbamic acid tert-butyl ester 
• 1386459-91-1 3-aminomethyl-5-chloro-4-fluoro-benzonitrile 
• 1386459-89-7 [3-chloro-2-fluoro-5-(2H-tetrazol-5-yl)-benzyl]-carbamic acid tert-butyl ester 
• 1386459-88-6 (3-chloro-5-cyano-2-fluoro-benzyl)-carbamic acid tert-butyl ester 
• 1386461-57-9 3-aminomethyl-5-chloro-4-fluoro-benzoic acid methyl ester 

Relevant academic research and scientific papers

ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS

The present disclosure provides pharmaceutical compositions comprising aryl sulfonamide Stat3 small molecule inhibitors and certain pharmaceutically acceptable salts thereof, and methods of their use for treating cancer.

HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Disclosed in the present invention are a heterocyclic compound, an application thereof and a pharmaceutical composition comprising the same. Provided by the present invention are a heterocyclic compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has a novel structure and a good inhibitory activity against autotaxin (ATX).

Fragment-based discovery of JAK-2 inhibitors

Fragment-based hit identification coupled with crystallographically enabled structure-based drug design was used to design potent inhibitors of JAK-2. After two iterations from fragment 1, we were able to increase potency by greater than 500-fold to provide sulfonamide 13, a 78-nM JAK-2 inhibitor.